Jun 6 |
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
|
Jun 4 |
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
|
Jun 3 |
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
|
May 15 |
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
May 15 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
|
May 14 |
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
|
May 2 |
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
|
Apr 30 |
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
Apr 25 |
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
|
Apr 1 |
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
|